What is the role of osimertinib (Tagrisso) in the treatment of non-small cell lung cancer (NSCLC)?

Updated: Aug 21, 2019
  • Author: Maurie Markman, MD, MS; Chief Editor: Keith K Vaux, MD  more...
  • Print


Finally, the EGFR mutation T790M is found in approximately half of patients with acquired resistance EGFR-TKIs. [27] However, discontinuation of treatment can lead to a more rapid progression of disease regardless of T790M mutation status. [28] Because the presence of this mutation should not necessarily preclude continued use of EGFR-TKIs, the clinical relevance of routine testing in patients demonstrating treatment resistance is unknown. The first EGFR inhibitor that targets T790M, osimertinib (Tagrisso), was approved in the United States in November 2015. It is indicated for metastatic epidermal growth factor receptor (EGFR) T790M mutation–positive non-small cell lung cancer (NSCLC), as detected by an FDA approved test, in patients who have progressed during or after EGFR TKI therapy. [29]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!